Given this clinical importance of PAI-1 levels related to severity of human diseases, inhibitors have been synthesized and some inhibitors are under clinical trials in various diseases including ovarian cancer, alzheimer’s disease, cardiovascular disease, pulmonary fibrosis renal diseases and liver diseases [36–39]. Here, SERPINE1 is linked to liver disorder.